Authors
Loading...
Randomized trial finds ENO1 and PKM interactions drive HBV-related HCC progression, suggesting new therapeutic targets.
Hu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: